News articles about Cambrex (NYSE:CBM) have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cambrex earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 48.0441103659888 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Shares of Cambrex (NYSE CBM) opened at $52.25 on Friday. The firm has a market cap of $1,706.39, a P/E ratio of 17.02, a PEG ratio of 1.26 and a beta of 2.38. Cambrex has a 1-year low of $42.55 and a 1-year high of $62.95.

Cambrex (NYSE:CBM) last announced its quarterly earnings data on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.10 by $0.17. The firm had revenue of $182.28 million during the quarter, compared to analyst estimates of $181.39 million. Cambrex had a net margin of 19.17% and a return on equity of 22.42%. The business’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.23 EPS. equities analysts forecast that Cambrex will post 2.76 EPS for the current year.

CBM has been the subject of a number of research reports. Craig Hallum reissued a “buy” rating and issued a $60.00 price target (down previously from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. Zacks Investment Research raised shares of Cambrex from a “strong sell” rating to a “hold” rating in a research note on Monday, January 15th. William Blair initiated coverage on shares of Cambrex in a research note on Tuesday, January 16th. They issued an “outperform” rating for the company. Finally, Longbow Research cut shares of Cambrex from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 14th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $60.00.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at

About Cambrex

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Insider Buying and Selling by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with's FREE daily email newsletter.